Phase 2 Epilepsy Trial, Recruiting (NCT06819670)

Phase 2 Epilepsy Trial, Recruiting NCT06819670 Sponsor: University of California, Los Angeles Condition: Epilepsy

Printed from Voxsanity (voxsanity.com.au) — NCT06819670 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Epilepsy

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

The child is between 2 and 18 months old (inclusive)
The child has been diagnosed with infantile spasms syndrome and brain wave testing (EEG) has confirmed that their spasms fully responded to standard treatments (such as prednisolone, ACTH, and/or vigabatrin)

Who may not be able to join:

The child has significantly high blood pressure, an active infection, or another health condition that the study doctor considers too risky alongside extended steroid treatment
The child has used any unofficial or homemade cannabis-based product within the 14 days before the screening visit
The child is currently following a ketogenic (very high fat, low carbohydrate) diet as part of their treatment
The child has had a vagal nerve stimulator (a device implanted to help control seizures) fitted within the past 3 months, or has had the device's settings changed within the past month
The child's infantile spasms syndrome was treated through epilepsy surgery

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 26 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Shaun A. Hussain, MD, MS, University of California, Los Angeles

Phone: 310-206-7630

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06819670

Sponsor: University of California, Los Angeles

Phase: Phase 2

Status: Recruiting

Condition: Epilepsy

Trial contact: 310-206-7630

More information: https://clinicaltrials.gov/study/NCT06819670

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

The child is between 2 and 18 months old (inclusive)
The child has been diagnosed with infantile spasms syndrome and brain wave testing (EEG) has confirmed that their spasms fully responded to standard treatments (such as prednisolone, ACTH, and/or vigabatrin)

Who may not be able to join:

The child has significantly high blood pressure, an active infection, or another health condition that the study doctor considers too risky alongside extended steroid treatment
The child has used any unofficial or homemade cannabis-based product within the 14 days before the screening visit
The child is currently following a ketogenic (very high fat, low carbohydrate) diet as part of their treatment
The child has had a vagal nerve stimulator (a device implanted to help control seizures) fitted within the past 3 months, or has had the device's settings changed within the past month
The child's infantile spasms syndrome was treated through epilepsy surgery

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 26 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

University of California, Los Angeles

Registry

ClinicalTrials.gov

Start date

5 May 2025

Est. completion

28 February 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Incidence of treatment-emergent adverse events; Incidence of epileptic spasms relapse

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov